Posttraumatic stress disorder (PTSD) and major depressive disorder are often comorbid in humans. Psilocybin reportedly has beneficial therapeutic effects on depression, possibly by promoting neuroplasticity. PTSD is associated with the dysregulation of neuroplasticity in the hippocampus and medial prefrontal cortex (mPFC). We hypothesized that psilocybin might reduce fear memory by promoting neuroplasticity in the hippocampus and mPFC.
Aims:
We investigated the effects of psilocybin on fear memory and explored its underlying mechanisms. We generated a mouse model of PTSD via auditory-cued fear conditioning and treated the mice with either vehicle or psilocybin (2.5 mg/kg, intraperitoneal) on day 0. Fear memory was assessed by the percentage of freezing time in response to conditioned stimuli. Fear memory tests were conducted on days 1, 6, and 7, after which the mice were sacrificed. To investigate the role of neuroplasticity in mediating the effects of psilocybin on fear memory, we assessed structural neuroplasticity and neuroplasticity-associated marker protein levels in the hippocampus and mPFC 7 days after a single dose of psilocybin.
Results:
Psilocybin reduced the cue-induced fear response on days 1, 6, and 7. Psilocybin ameliorated the fear conditioning-induced decreases in neuroplasticity in the hippocampus and mPFC. Through Golgi-Cox staining, Western blotting, and immunofluorescence staining, we found that psilocybin increased dendritic branches and spine density, upregulated GluR1 and synapsin-1, enhanced brain-derived neurotrophic factor and mammalian target of rapamycin signaling, and promoted neurogenesis.
Conclusions:
A single dose of psilocybin reduces both the rapid and sustained fear memory in mice, at least in part by restoring neuroplasticity in the hippocampus and mPFC. These findings indicate that psilocybin has significant potential for use in the treatment of PTSD and other mental disorders characterized by fear memory.
AlmeidaFBBarrosHMTPinnaG (2021) Neurosteroids and neurotrophic factors: What is their promise as biomarkers for major depression and PTSD?International Journal of Molecular Sciences22(4): 1758.
2.
BirdCIVModlinNLRuckerJJH (2021) Psilocybin and MDMA for the treatment of trauma-related psychopathology. International Review of Psychiatry33(3): 229–249.
3.
BremnerJDRandallPScottTM, et al. (1995) MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. American Journal of Psychiatry152(7): 973–981.
4.
CameronLPTombariRJLuJ, et al. (2021) A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature589(7842): 474–479.
5.
Carhart-HarrisRGiribaldiBWattsR, et al. (2021) Trial of psilocybin versus escitalopram for depression. The New England Journal of Medicine384(15): 1402–1411.
6.
Carhart-HarrisRLBolstridgeMRuckerJ, et al. (2016) Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry3(7): 619–627.
7.
CatlowBJSongSParedesDA, et al. (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Experimental Brain Research228(4): 481–491.
8.
ChiTGoldJA (2020) A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. Journal of the Neurological Sciences411: 116715.
9.
DavisAKBarrettFSMayDG, et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry78(5): 481–489.
10.
DuYLiYZhaoX, et al. (2023) Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity. Chinese Medical Journal (English)136(24): 2983–2992.
11.
DumanRSDeyamaSFogacaMV (2021) Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants. European Journal of Neurosciences53(1): 126–139.
12.
GoodwinGMAaronsonSTAlvarezO, et al. (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. The New England Journal of Medicine387(18): 1637–1648.
13.
GriffithsRRJohnsonMWCarducciMA, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology30(12): 1181–1197.
14.
GukasyanNDavisAKBarrettFS, et al. (2022) Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology36(2): 151–158.
15.
HagsäterSMPetterssonRPetterssonC, et al. (2021) A complex impact of systemically administered 5-HT2A receptor ligands on conditioned fear. International Journal of Neuropsychopharmacology24(9): 749–757.
16.
HeMWeiJXMaoM, et al. (2018) Synaptic plasticity in PTSD and associated comorbidities: The function and mechanism for diagnostics and therapy. Current Pharmaceutical Design24(34): 4051–4059.
17.
HolzeFLeyLMullerF, et al. (2022) Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology47(6): 1180–1187.
18.
JefsenOHElfvingBWegenerG, et al. (2021) Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. Journal of Psychopharmacology35(4): 483–493.
19.
JungYSeoJYRyuHG, et al. (2020) BDNF-induced local translation of GluA1 is regulated by HNRNP A2/B1. Science Advances6(47): eabd2163.
20.
KarlASchaeferMMaltaLS, et al. (2006) A meta-analysis of structural brain abnormalities in PTSD. Neuroscience & Biobehavioral Reviews30(7): 1004–1031.
21.
KarpovaNNPickenhagenALindholmJ, et al. (2011) Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science334(6063): 1731–1734.
22.
KhanAJBradleyEO’DonovanA, et al. (2022) Psilocybin for trauma-related disorders. Current Topics in Behavioral Neurosciences56: 319–332.
23.
KlempinFKronenbergGCheungG, et al. (2011) Properties of doublecortin-(DCX)-expressing cells in the piriform cortex compared to the neurogenic dentate gyrus of adult mice. PLoS One6(10): e25760.
24.
KopecCDRealEKesselsHW, et al. (2007) GluR1 links structural and functional plasticity at excitatory synapses. Journal of Neurosciences27(50): 13706–13718.
25.
KredietEBostoenTBreeksemaJ, et al. (2020) Reviewing the potential of psychedelics for the treatment of PTSD. International Journal of Neuropsychopharmacology23(6): 385–400.
26.
LaiCSFrankeTFGanWB (2012) Opposite effects of fear conditioning and extinction on dendritic spine remodelling. Nature483(7387): 87–91.
27.
LonsdorfTBMenzMMAndreattaM, et al. (2017) Don’t fear ‘fear conditioning’: Methodological considerations for the design and analysis of studies on human fear acquisition, extinction, and return of fear. Neuroscience & Biobehavioral Reviews77: 247–285.
28.
LoweHToyangNSteeleB, et al. (2021) The therapeutic potential of psilocybin. Molecules26(10): 2948.
29.
LyCGrebACCameronLP, et al. (2018) Psychedelics promote structural and functional neural plasticity. Cell Reports23(11): 3170–3182.
30.
MadrasBK (2022) Psilocybin in treatment-resistant depression. The New England Journal of Medicine387(18): 1708–1709.
31.
MaheuMESharmaSKingG, et al. (2022) Amygdala DCX and blood Cdk14 are implicated as cross-species indicators of individual differences in fear, extinction, and resilience to trauma exposure. Molecular Psychiatry27(2): 956–966.
32.
MetaxaAMClarkeM (2024) Efficacy of psilocybin for treating symptoms of depression: Systematic review and meta-analysis. BMJ385: e078084.
33.
MurnaneKS (2019) Serotonin 2A receptors are a stress response system: Implications for post-traumatic stress disorder. Behavioural Pharmacology30(2 and 3-Spec Issue): 151–162.
34.
NotarasMvan den BuuseM (2020) Neurobiology of BDNF in fear memory, sensitivity to stress, and stress-related disorders. Molecular Psychiatry25(10): 2251–2274.
35.
Pilar-CuellarFCastroEBretinS, et al. (2019) S 47445 counteracts the behavioral manifestations and hippocampal neuroplasticity changes in bulbectomized mice. Progress in Neuro-Psychopharmacology & Biological Psychiatry93: 205–213.
36.
RavalNRJohansenADonovanLL, et al. (2021) A single dose of psilocybin increases synaptic density and decreases 5-HT(2A) receptor density in the pig brain. International Journal of Molecular Sciences22(2): 835.
37.
RossSBossisAGussJ, et al. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology30(12): 1165–1180.
38.
ShalevALiberzonIMarmarC (2017) Post-traumatic stress disorder. The New England Journal of Medicine376(25): 2459–2469.
39.
ShaoLXLiaoCGreggI, et al. (2021) Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron109(16): 2535–2544.e2534.
40.
SiegelJSSubramanianSPerryD, et al. (2024) Psilocybin desynchronizes the human brain. Nature632(8023): 131–138.
41.
WangXXieHChenT, et al. (2021) Cortical volume abnormalities in posttraumatic stress disorder: An ENIGMA-psychiatric genomics consortium PTSD workgroup mega-analysis. Molecular Psychiatry26(8): 4331–4343.
42.
WoodburnSCLevittCMKoesterAM, et al. (2024) Psilocybin facilitates fear extinction: Importance of dose, context, and serotonin receptors. ACS Chemical Neuroscience15(16): 3034–3043.
43.
XuZGeronEPérez-CuestaLM, et al. (2023) Generalized extinction of fear memory depends on co-allocation of synaptic plasticity in dendrites. Nature Communications14(1): 503.
44.
YabukiYFukunagaK (2019) Clinical therapeutic strategy and neuronal mechanism underlying post-traumatic stress disorder (PTSD). International Journal of Molecular Sciences20(15): 3614.
45.
YerubandiAThomasJEBhuiyaN, et al. (2024) Acute adverse effects of therapeutic doses of psilocybin: A systematic review and meta-analysis. JAMA Network Open7(4): e245960.
46.
ZhangCWuXCLiS, et al. (2021) Perinatal low-dose bisphenol AF exposure impairs synaptic plasticity and cognitive function of adult offspring in a sex-dependent manner. Science of the Total Environment788: 147918.
47.
ZhangFRaoSCaoH, et al. (2022) Genetic evidence suggests posttraumatic stress disorder as a subtype of major depressive disorder. Journal of Clinical Investigation132(3) :e145942.
